This document (the “Business Plan”) has been prepared to assist prospective equity investors, development-finance institutions and lenders in evaluating a possible participation in the funding of HarmonyBridge Children’s Health & Rehabilitation Centres (the “Company” or “HarmonyBridge”). It does not constitute an offer, invitation or recommendation to subscribe for or purchase any securities, nor shall it form the basis of any contract or investment decision.
The financial projections are forward-looking. Headline revenue and EBITDA margin reflect the sponsor’s commercial projections and are preserved exactly; EBITDA is derived from them. Everything beneath EBITDA, component depreciation, interest on healthcare term debt, South African corporate taxation and working capital, has been independently re-derived by the analyst on a stated set of assumptions, and a two-round funding structure (a Series A and a later Series B, each blending equity and term debt) has been modelled to fund the phased national rollout. The balance sheet ties to zero in every year by construction and is machine-verified. Where the re-derivation surfaces material findings, most importantly the capital-intensity J-curve of early-year losses during the build and occupancy ramp, these are disclosed transparently in Section 18 rather than smoothed. Actual results may differ materially.
The leadership and shareholding described in Section 13 are the proposed structure for the enterprise being established, to be finalised on funding. Healthcare-market statistics are directional estimates from public industry sources current to mid-2026 and should be re-verified in due diligence. By accepting this Business Plan, the recipient agrees to keep its contents confidential.
NoteOn the figures in this plan
Revenue and EBITDA margin are preserved exactly as briefed (EBITDA is derived as revenue × margin). All statements below EBITDA are independently modelled: component depreciation on the facilities, medical equipment and digital systems; interest on healthcare term debt; 27% corporate tax with assessed-loss carry-forward; and working capital. Consistent with the invitation to structure the raise across funding rounds, the plan models a R700 million Series A (Year 1) and a R600 million Series B (Year 3), each blending equity and term debt. Because the flagship and network are built and financed ahead of maturing occupancy, the business is loss-making in Years 1–3 on a fully-loaded basis, the normal healthcare-infrastructure J-curve, before turning strongly profitable. This is disclosed up front, not smoothed.